title: Recent progress in end-stage hypertrophic cardiomyopathy.
abstract: Within the diverse spectrum of hypertrophic cardiomyopathy (HCM), a unique subgroup characterized by left ventricular enlargement and systolic dysfunction has emerged (defined as end-stage HCM [ES-HCM]). This underestimated entity provides challenging treatment strategies for extremely high risk of refractory heart failure and sudden cardiac death. Over the last 2 decades, the clinical features of ES-HCM have expanded and the underlying mechanisms gradually elucidated. Moreover, there is increasing evidence for early recognition of ES-HCM. New insights into early prevention and management will improve the clinical outcomes of this entity.
authors.affiliation: Departments of Cardiology (YX, K-QY, X-LZ) and Echocardiology (YJ), State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xiao
authors.forename: Kun-Qi
authors.initials: KQ
authors.lastname: Yang
authors.forename: Yong
authors.initials: Y
authors.lastname: Jiang
authors.forename: Xian-Liang
authors.initials: XL
authors.lastname: Zhou
mesh_terms: D024741:Cardiomyopathy, Hypertrophic, Familial / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control; D019468:Disease Management; D018450:Disease Progression; D042241:Early Diagnosis; D054143:Heart Failure, Systolic / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D012720:Severity of Illness Index